share_log

T2 Biosystems | 424B5: Prospectus

T2 Biosystems | 424B5: Prospectus

T2 Biosystems | 424B5：募资说明书
美股SEC公告 ·  08/23 16:33

Moomoo AI 已提取核心信息

T2 Biosystems, a company trading under the symbol TTOO on the Nasdaq Capital Market, has filed a prospectus supplement on August 23, 2024, to increase the maximum amount of shares available for sale under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The supplement amends the previous sales agreement prospectus dated July 29, 2024, raising the potential offering to $13,390,000 of common stock. This adjustment is in accordance with the offering limitations set by General Instruction I.B.6 of Form S-3, which restricts the company to sell securities in public primary offerings up to one-third of its public float within a 12-month period, as long as the public float is below $75 million. As of June 24, 2024, the aggregate market value of T2 Biosystems' common stock held by non-affiliates was $48,487,620. The company has previously sold $2,772,114 of securities in the 12 months leading up to the date of the prospectus supplement. The last reported sale price of T2 Biosystems' common stock was $3.50 per share on August 22, 2024.
T2 Biosystems, a company trading under the symbol TTOO on the Nasdaq Capital Market, has filed a prospectus supplement on August 23, 2024, to increase the maximum amount of shares available for sale under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The supplement amends the previous sales agreement prospectus dated July 29, 2024, raising the potential offering to $13,390,000 of common stock. This adjustment is in accordance with the offering limitations set by General Instruction I.B.6 of Form S-3, which restricts the company to sell securities in public primary offerings up to one-third of its public float within a 12-month period, as long as the public float is below $75 million. As of June 24, 2024, the aggregate market value of T2 Biosystems' common stock held by non-affiliates was $48,487,620. The company has previously sold $2,772,114 of securities in the 12 months leading up to the date of the prospectus supplement. The last reported sale price of T2 Biosystems' common stock was $3.50 per share on August 22, 2024.
t2 biosystems，一家在纳斯达克资本市场以TTOO作为股票代码交易的公司，于2024年8月23日提交了一份补充招股说明书，以增加其与H.C. Wainwright & Co.，LLC签订的市场销售协议下可供销售的最大股份数。该补充招股说明书修改了之前于2024年7月29日的销售协议招股说明书，将潜在的发行规模提高到1339万美元。此调整符合Form S-3的I.b.6条款的发行限制，该条款限制公司在12个月内通过公开首次发行仅能出售其公众流通股份的三分之一，前提是公众流通股份低于7500万美元。截至2024年6月24日，T2 Biosystems的非关联方持有的普通股的总市值为48,487,620美元。该公司在招股说明书补充之前的12个月内已出售了2,772,114美元的证券。T2 Biosystems的普通股最后报告的成交价格为2024年8月22日每股3.50美元。
t2 biosystems，一家在纳斯达克资本市场以TTOO作为股票代码交易的公司，于2024年8月23日提交了一份补充招股说明书，以增加其与H.C. Wainwright & Co.，LLC签订的市场销售协议下可供销售的最大股份数。该补充招股说明书修改了之前于2024年7月29日的销售协议招股说明书，将潜在的发行规模提高到1339万美元。此调整符合Form S-3的I.b.6条款的发行限制，该条款限制公司在12个月内通过公开首次发行仅能出售其公众流通股份的三分之一，前提是公众流通股份低于7500万美元。截至2024年6月24日，T2 Biosystems的非关联方持有的普通股的总市值为48,487,620美元。该公司在招股说明书补充之前的12个月内已出售了2,772,114美元的证券。T2 Biosystems的普通股最后报告的成交价格为2024年8月22日每股3.50美元。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间